1.
Migden M, Lear J, Squittieri N, Liu L, Guminski A, Dummer R. Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind. J of Skin [Internet]. 2020Sep.2 [cited 2022Jul.5];4(5):s68. Available from: https://www.jofskin.org/index.php/skin/article/view/1017